Copyright ©The Author(s) 2021.
World J Hepatol. Dec 27, 2021; 13(12): 1991-2004
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.1991
Table 1 Summary management strategies
Lifestyle modificationsDietary modification
Exercise/ physical activity
Avoid heavy alcohol consumption
Benefit with coffee consumption
PharmacotherapyNo approved drug for MAFLD in post liver transplants patients
Bariatric treatmentSurgery
Tailored ImmunosuppressionEarly taper of steroids
Decreasing CNIs as possible
Avoid/cautious use of mTOR inhibitors
Table 2 Summary of clinical significances and outcomes of de novo and recurrent metabolic dysfunction-associated fatty liver disease in post liver transplant patients

De novo MAFLD
Recurrent MAFLD
Risk factors/Predictors for post LT MAFLDPost LT weight gainPost LT weight gain
HCVPost-transplant hypertriglyceridemia
Sirolimus-based immunosuppressant therapySteroid
Insulin resistance/diabetes mellitusPost LT Metabolic syndrome
Insulin use
Insulin resistance/ diabetes mellitus
Progression to steatohepatitis and advanced fibrosisLess commonMore common
Cardiovascular eventsCommonCommon
Patient and graft survivalNo significant impactNo significant impact